Other substances

Ascorbic acid

A glucose vitamin derivate.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Natural product

2
 Supporting references
0
 Contradictory references
65
 AI-suggested references
34
 Clinical trials

General information

Ascorbic acid is a water-soluble vitamin and an essential nutrient in human diet. It is involved in multiple biological processes. Ascorbic acid is a potent antioxidant (NCIt).

Ascorbic acid on DrugBank
Ascorbic acid on PubChem
Ascorbic acid on Wikipedia

Synonyms

Vitamin C; L-ascorbic acid

Marketed as

ASCOLTIN; ASCOR; ASCORBIC ACID; ASCORBICAP; VITAMIN C

 

Structure image - Ascorbic acid

C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O

Supporting references

Link Tested on Impact factor Notes Publication date
Beneficial aspects of high dose intravenous vitamin C on patients with COVID-19 pneumonia in severe condition: a retrospective case series study
Severe severity Small molecule Critical severity Case series 		Severe to critical pneumonia patients 1.37

Early administration of high-dose intravenous ascorbic acid (vitamin C) in severe or critical COVID-19 patients was linked to improvement in CRP, lymphocyte counts, CD4+ T cell counts, oxygenation, and sequential organ failure assessment score. Sample size: 6 severe + 6 critical. Dosage: IV administered 162.7 mg/kg (median) in severe; 178.6 mg/kg (median) in critical.


 Nov/17/2020
The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study
Severe severity Small molecule Critical severity Moderate severity Cohort study 		Patients 4.83

Observed decrease in 28-day mortality in patients treated with high-dose vitamin C compared to standard of care control. The treatment reduced the levels of some of the inflammatory markers and was associated with better improvement in supplementary oxygen requirements. The subgroup analysis implied that clinical improvement observed in the high-dose vitamin C group was better in patients ≤60 years of age, those receiving low-flow oxygen therapy, and the ones with high-sensitivity CRP below 1 mg/l. Adverse events were not associated with the treatment. Sample size: 46 (high-dose) + 30 (standard therapy) control. Dosage: 6 g IV twice a day on day 1; 6 g daily on days 2-5. Primary outcomes: 28-day mortality and clinical improvement.


 Feb/26/2021

AI-suggested references

Link Publication date
Use of Intravenous Vitamin C in Critically Ill Patients With COVID-19 Infection.
Jun/08/2021
Vitamin D (Cholecalciferol) with Low Dose Vitamin C as a Safe and Effective Therapeutic Modality in an Adult with COVID-19 Pneumonia.
Jun/26/2020
An investigation into the Effects of Intravenous Vitamin C on Pulmonary CT Findings and Clinical Outcomes of Patients with COVID 19 Pneumonia A Randomized Clinical Trial.
Mar/21/2022
Effect of ArtemiC in patients with COVID-19: A Phase II prospective study.
May/21/2020
Vitamin C inhibits Angiotensin-Converting Enzyme-2 in Isolated Rat Aortic Ring.
Dec/16/2021
Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix (RJX).
Oct/14/2020
Promising therapeutic approach for SARS-CoV-2 infection by using a rutin-based combination therapy.
May/24/2022
Combinatorial approach of vitamin C derivative and anti-HIV drug-darunavir against SARS-CoV-2.
Sep/06/2021
Fabrication, DFT Calculation, and Molecular Docking of Two Fe(III) Imine Chelates as Anti-COVID-19 and Pharmaceutical Drug Candidate.
Jul/30/2020
Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial
Jun/09/2020
A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2.
Nov/30/2020
Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study
Sep/03/2021
Efficacy of diammonium glycyrrhizinate combined with vitamin C for treating hospitalized COVID-19 patients: a retrospective, observational study
Jan/13/2022
Hypothesis of zinc ascorbate as best zinc ionophore for raising antiviral resistance against Covid-19
May/28/2021
The Effect of Vitamin C on Pathological Parameters and Survival Duration of Critically Ill Coronavirus Disease 2019 Patients: A Randomized Clinical Trial
Dec/15/2021
High-dose vitamin C ameliorates cardiac injury in COVID-19 pandemic: a retrospective cohort study
Sep/09/2021
The vital role of animal, marine, and microbial natural products against COVID-19
Mar/03/2022
Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection
Feb/01/2021
The History of Methylprednisolone, Ascorbic Acid, Thiamine, and Heparin Protocol and I-MASK+ Ivermectin Protocol for COVID-19.
Apr/06/2021
Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19)
Jun/19/2020
High Dose Intravenous Vitamin C for Preventing The Disease Aggravation of Moderate COVID-19 Pneumonia. A Retrospective Propensity Matched Before-After Study.
Apr/22/2021
Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial
Jan/25/2021
Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan.
Apr/30/2020
Treatment of COVID-19 patients with quercetin: a prospective, single center, randomized, controlled trial
Dec/24/2021
Possible Prophylactic Approach for SARS-CoV-2 Infection by Combination of Melatonin, Vitamin C and Zinc in Animals.
Dec/03/2020
No significant benefit of moderate-dose vitamin C on severe COVID-19 cases
Sep/17/2022
In Vitro Determination of Inhibitory Effects of Humic Substances Complexing Zn and Se on SARS-CoV-2 Virus Replication
Jan/13/2021
High Dose Intravenous Vitamin C as Adjunctive Therapy for COVID-19 Patients with Cancer: Two Cases
Aug/30/2020
Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial
Feb/11/2021
Investigation of the disease process and drug combinations in patients with suspected/confirmed COVID-19 using favipiravir
Mar/29/2021
Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: findings from a prospective, exploratory, open-labeled, comparative, randomized c
Sep/15/2021
Evaluation of the Effects of Favipiravir Combined with Vitamin C on Alveolar Bone in Rats.
May/16/2022
Effect of high-dose intravenous vitamin C on prognosis in patients with SARS-CoV-2 pneumonia.
May/11/2021
Protective effect of vitamin C against ivermectin induced nephrotoxicity in different age groups of male wistar rats: bio-histopathological study
Feb/07/2020
Vitamin C and COVID-19
Jan/18/2021
High-dose intravenous vitamin C decreases rates of mechanical ventilation and cardiac arrest in severe COVID-19
Aug/11/2021
Metabolomic profiling of three Araucaria species, and their possible potential role against COVID-19
Nov/11/2021
Surface-engineered liposomal particles of calcium ascorbate with fenugreek galactomannan enhanced the oral bioavailability of ascorbic acid: a randomized, double-blinded, 3-sequence, crossover study
May/30/2020
Therapeutic targets and signaling mechanisms of vitamin C activity against sepsis: a bioinformatics study
May/13/2020
Pilot trial of high-dose vitamin C in critically ill COVID-19 patients
Jan/09/2021
Integrative pharmacological mechanism of vitamin C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses
Sep/02/2021
Severe acute respiratory syndrome coronavirus 2 ORF3a induces the expression of ACE2 in oral and pulmonary epithelial cells and the food supplement Vita Deyun diminishes this effect.
Mar/16/2021
The use of IV vitamin C for patients with COVID-19: a case series
Aug/27/2021
Efficacy and safety of Guduchighana Vati in asymptomatic and mild-to-moderate cases of coronavirus disease-19: A randomized controlled pilot study
Feb/24/2022
Inhibition of ACE2 Expression by Ascorbic Acid Alone and its Combinations with Other Natural Compounds
May/10/2021
Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID-19
May/07/2020
The Role of Vitamin C as Adjuvant Therapy in COVID-19
Nov/30/2020
Preclinical Efficacy and Safety Studies of Formulation SSV-003, a Potent Anti-Viral Herbal Formulation
Dec/30/2020
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Dec/08/2020
Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants
Jan/21/2022
Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial
Apr/01/2021
Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients
Jun/17/2020
Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs
May/19/2021
Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19
Jun/24/2021
Megadose Methylprednisolone for Immune Thrombocytopenia in an Infant Positive for SARS-CoV-2: A Case Report
Sep/02/2021
Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi-Organ Failure.
Nov/10/2020
A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis
Mar/03/2022
Effects of vitamin C and D on the mRNA expression of angiotensin converting enzyme 2 receptor, cathepsin L, and transmembrane serine protease in the mouse lungs
Mar/22/2022
Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs
Feb/07/2022
Recent Clinical Trials on Natural Products and Traditional Chinese Medicine Combating the COVID-19
May/29/2020
Antiviral and Immunomodulatory Effects of Phytochemicals from Honey against COVID-19: Potential Mechanisms of Action and Future Directions
Oct/29/2020
Early high-dose vitamin C in post-cardiac arrest syndrome (VITaCCA): study protocol for a randomized, double-blind, multi-center, placebo-controlled trial.
Aug/18/2021
High-dose intravenous vitamin C attenuates hyperinflammation in severe coronavirus disease 2019.
Jun/26/2021
Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial.
Apr/20/2021
Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial.
Aug/20/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT05283954 Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea Not yet recruiting Phase 2|Phase 3 May/01/2022 Jul/30/2022
  • Alternative id - Fluo-Pred-Iver
  • Interventions - Drug: Combination regimen: Fluoxetine, Prednisolone, Ivermectin|Drug: Combination regimen: Albendazole, Vitamin C
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 954
  • Age - 18 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - COVID-19 disease progression|SARS-CoV-2 viral load|COVID-19 WHO Clinical progression scale score|Adverse Events
NCT02735707 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Recruiting Phase 3 Apr/11/2016 Dec/01/2025
  • Alternative id - U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584
  • Interventions - Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Standard course macrolide|Drug: Extended course macrolide|Other: No systemic corticosteroid|Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Fixed-duration higher dose Hydrocortisone|Other: No antiviral agent for influenza|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Other: No antiviral agent for COVID-19|Drug: Lopinavir / Ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Ivermectin|Other: No immune modulation for COVID-19|Drug: Interferon beta-1a|Drug: Anakinra|Drug: Tocilizumab|Drug: Sarilumab|Drug: Local standard venous thromboprophylaxis|Drug: Therapeutic anticoagulation|Drug: Conventional low dose thromboprophylaxis|Drug: Intermediate dose thromboprophylaxis|Drug: Continuation of therapeutic dose anticoagulation|Other: No immunoglobulin|Biological: Convalescent plasma|Biological: Delayed administration of convalescent plasma|Other: No vitamin C|Drug: Vitamin C|Other: No antiplatelet|Drug: Aspirin|Drug: P2Y12 inhibitor|Other: No simvastatin|Drug: Simvastatin|Other: Placebo|Drug: Eritoran|Drug: Apremilast|Procedure: Clinician-preferred mechanical ventilation strategy|Procedure: Protocolised mechanical ventilation strategy|Other: No renin-angiotensin system inhibitor|Drug: Angiotensin converting enzyme inhibitor|Drug: Angiotensin Receptor Blockers|Drug: ARB + DMX-200|Other: No cysteamine|Drug: Cysteamine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Florida, Jacksonville, Florida, United States|Augusta University, Augusta, Georgia, United States|University of Illinois Health, Chicago, Illinois, United States|Tulane Medical Center, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|Brown University - Rhode Island Hospital, Providence, Rhode Island, United States|Canberra Hospital, Canberra, Australian Capital Territory, Australia|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Sutherland Hospital, Caringbah, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|Dubbo Base Hospital, Dubbo, New South Wales, Australia|Northern Beaches Hospital, Frenchs Forest, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|St. George Hospital, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|John Hunter Hospital, Newcastle, New South Wales, Australia|Orange Health Service, Orange, New South Wales, Australia|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|The Prince Charles Hospital, Brisbane, Queensland, Australia|Mater Hospital Brisbane, Brisbane, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Caboolture Hospital, Caboolture, Queensland, Australia|Queen Elizabeth II Jubilee Hospital, Coopers Plains, Queensland, Australia|Logan Hospital, Logan, Queensland, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|Rockhampton Hospital, Rockhampton, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|Townsville Hospital, Townsville, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Lyell McEwin Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Launceston Hospital, Launceston, Tasmania, Australia|Ballarat Base Hospital, Ballarat, Victoria, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|Casey Hospital, Berwick, Victoria, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Dandenong Hospital, Dandenong, Victoria, Australia|Angliss Hospital, Ferntree Gully, Victoria, Australia|Footscray Hospital, Footscray, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Maroondah Hospital, Ringwood East, Victoria, Australia|Sunshine Hospital, Sunshine, Victoria, Australia|Werribee Mercy Hospital, Werribee, Victoria, Australia|St John of God Hospital Midland, Midland, Western Australia, Australia|St John of God Hospital Murdoch, Murdoch, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Subiaco, Subiaco, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Foothills Medical Centre, Calgary, Alberta, Canada|Peter Lougheed Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|South Health Campus, Calgary, Alberta, Canada|Royal Alexandra Hospital, Alberta, Edmonton, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|St Boniface General Hospital, Winnipeg, Manitoba, Canada|Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada|Grace Hospital, Winnipeg, Manitoba, Canada|Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick, Canada|The Moncton Hospital, Fredericton, New Brunswick, Canada|The Saint John General Hospital, Fredericton, New Brunswick, Canada|William Osler Health System, Brampton, Ontario, Canada|Brantford General Hospital, Brantford, Ontario, Canada|Hamilton general Hospital, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St Mary's General Hospital, Kitchener, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Niagara Health, Saint Catharines, Ontario, Canada|Thunder Bay General Hospital, Thunder Bay, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|St Joseph's Health Centre, Toronto, Ontario, Canada|CIUSS Chaudieres-Appalaches (Levis), Lévis, Quebec, Canada|Hospital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Hôpital Fleury, Montréal, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montréal, Quebec, Canada|CHU de Québec - Université Laval, Québec, Quebec, Canada|IUCPQ-UL, Québec, Quebec, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Quebec, Canada|Regina General Hospital, Saskatoon, Saskatchewan, Canada|Universidad de La Sabana, Chía, Cundinamarca, Colombia|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Apollo Main Hospital, Chennai, Tamil Nadu, India|Apollo First Med Hospital, Chennai, Tamil Nadu, India|Apollo Vanagaram Hospital, Chennai, Tamil Nadu, India|Apollo Speciality Hospital - OMR, Chennai, Tamil Nadu, India|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|St. Marianna University Yokohama City Seibu Hospital, Yokohama, Kanagawa, Japan|Saiseikai Kumamoto Hospital, Minami, Kumamoto, Japan|Osaka City General Hospital, Osaka, Japan|Nerima Hikarigaoka Hospital, Tokyo, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Itabashi Chuo Medical Center, Tokyo, Japan|Tokyo bay Urayasu-Ichikawa Medical Center, Tokyo, Japan|Wakayama Medical University, Wakayama, Japan|Chitwan Medical College, Bharatpur, Nepal|Grande International Hospital, Kathmandu, Nepal|Hospital for Advanced Medicine and Surgery (HAMS), Kathmandu, Nepal|Nepal Mediciti, Kathmandu, Nepal|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Taranaki Base Hospital, New Plymouth, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Ziauddin University Hospital Clifton Campus, Karachi, Sindh, Pakistan|Abbasi Shaheed Hospital, Karachi, Sindh, Pakistan|National Institute of Cardiovascular Diseases, Karachi, Karachi, Sindh, Pakistan|South City Hospital, Karachi, Karachi, Sindh, Pakistan|Ziauddin University North Nazimabad Campus, Karachi, Sindh, Pakistan|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes", Bucharest, Romania|King Abdulaziz Medical City, Riyadh, Saudi Arabia|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basildon Hospital, Basildon, England, United Kingdom|Basingstoke and North Hampshire Hospital, Basingstoke, England, United Kingdom|Royal United Hospital, Bath, Bath, England, United Kingdom|Queen Elizabeth Hospital Birmingham, Birmingham, England, United Kingdom|Birmingham City Hospital, Birmingham, England, United Kingdom|Blackburn Hospital, Blackburn, England, United Kingdom|Pilgrim's Hospital, Boston, England, United Kingdom|Royal Bournemouth Hospital, Bournemouth, England, United Kingdom|Royal Sussex County Hospital, Brighton, England, United Kingdom|Southmead Hospital, Bristol, England, United Kingdom|Bristol Royal Hospital, Bristol, England, United Kingdom|Queen's Hospital, Burton, Burton on Trent, England, United Kingdom|Royal Papworth Hospital, Cambridge, England, United Kingdom|Addenbrookes Hospital, Cambridge, England, United Kingdom|Cumberland Royal Infirmary, Carlisle, England, United Kingdom|Ashford & St Peters Hospital Trust, Chertsey, England, United Kingdom|Chesterfield Royal Hospital, Chesterfield, England, United Kingdom|Countess of Chester Hospital, Chester, England, United Kingdom|Colchester Hospital, Colchester, England, United Kingdom|University Hospital Coventry, Coventry, England, United Kingdom|North Manchester General Hospital, Crumpsall, England, United Kingdom|Darlington Memorial Hospital, Darlington, England, United Kingdom|Darent Valley Hospital, Dartford, England, United Kingdom|Russells Hall Hospital, Dudley, England, United Kingdom|University Hospital of North Durham, Durham, England, United Kingdom|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom|Frimley Park Hospital, Frimley, England, United Kingdom|Queen Elizabeth Hospital, Gateshead, England, United Kingdom|Medway Maritime Hospital, Gillingham, England, United Kingdom|James Paget Kings Lynn Hospital, Great Yarmouth, England, United Kingdom|Royal Surrey County Hospital, Guildford, England, United Kingdom|Northwick Park Hospital, Harrow, England, United Kingdom|Hereford County Hospital, Hereford, England, United Kingdom|Barnet Hospital, High Barnet, England, United Kingdom|Huddersfield Hospital, Huddersfield, England, United Kingdom|King George Hospital, Ilford, England, United Kingdom|Ipswich Hospital, Ipswich, England, United Kingdom|Kettering Hospital, Kettering, England, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|Glenfield Hospital, Leicester, England, United Kingdom|Lincoln County Hospital, Lincoln, England, United Kingdom|Liverpool Heart and Chest Hospital, Liverpool, England, United Kingdom|Alder Hey Hospital, Liverpool, England, United Kingdom|Royal Liverpool Hospital, Liverpool, England, United Kingdom|University Hospital Aintree, Liverpool, England, United Kingdom|Croydon University Hospital, London, England, United Kingdom|Royal London Hospital, London, England, United Kingdom|Whipps Cross Hospital, London, England, United Kingdom|Newham Hospital, London, England, United Kingdom|St Barts Hosptial, London, England, United Kingdom|North Middlesex Hospital, London, England, United Kingdom|Royal Free Hospital, London, England, United Kingdom|St Thomas' Hospital, London, England, United Kingdom|Guy's Hospital, London, England, United Kingdom|King's College Hospital, London, England, United Kingdom|St George's Hospital, London, England, United Kingdom|Royal Marsden Hospital, London, England, United Kingdom|Ryal Brompton, London, England, United Kingdom|Hammersmith Hospital, London, England, United Kingdom|St Mary's Hospital, London, England, United Kingdom|Charing Cross Hospital, London, England, United Kingdom|Luton and Dunstable University Hospital, Luton, England, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, England, United Kingdom|Manchester Royal Infirmary, Manchester, England, United Kingdom|The Christie Hospital, Manchester, England, United Kingdom|Wythenshawe Hospital, Manchester, England, United Kingdom|Queen Elizabeth Hospital, Woolwich, Margate, England, United Kingdom|The James Cook University Hospital, Middlesbrough, England, United Kingdom|Milton Keynes University Hospital, Milton Keynes, England, United Kingdom|Royal Victoria Infirmary, Newcastle, Newcastle, England, United Kingdom|Newcastle Freeman Hospital, Newcastle, England, United Kingdom|Northampton General Hospital, Northampton, England, United Kingdom|Norfolk and Norwich University Hospital, Norwich, England, United Kingdom|City Hospital Nottingham, Nottingham, England, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, England, United Kingdom|George Eliot Hospital, Nuneaton, England, United Kingdom|Royal Oldham Hospital, Oldham, England, United Kingdom|Princess Royal University Hospital, Orpington, England, United Kingdom|John Radcliffe Hospital, Oxford, England, United Kingdom|Derriford Hospital, Plymouth, England, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, England, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, England, United Kingdom|Whiston Hospital, Prescot, England, United Kingdom|Royal Preston Hospital, Preston, England, United Kingdom|Royal Berkshire Hospital, Reading, England, United Kingdom|Alexandra Hospital, Redditch, Redditch, England, United Kingdom|Queen's Hospital Romford, Romford, England, United Kingdom|Rotherham General Hospital, Rotherham, England, United Kingdom|Salford Royal Hospital, Salford, England, United Kingdom|Salisbury District Hospital, Salisbury, England, United Kingdom|Royal Hallamshire Hospital, Sheffield, England, United Kingdom|Northern General Hospital, Sheffield, England, United Kingdom|Wexham Park Hospital, Slough, England, United Kingdom|South Tyneside District Hospital, South Shields, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Stepping Hill Hospital, Stockport, England, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, England, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, England, United Kingdom|Sunderland Hospital, Sunderland, England, United Kingdom|King's Mill Hospital, Sutton In Ashfield, England, United Kingdom|Great Western Hospital, Swindon, England, United Kingdom|Western General Hospital, Swindon, England, United Kingdom|Musgrove Park Hospital, Taunton, England, United Kingdom|Torbay and South Devon Hospital, Torquay, England, United Kingdom|Royal Cornwall Hospital, Truro, England, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, England, United Kingdom|Harefield Hospital, Uxbridge, England, United Kingdom|Watford General Hospital, Watford, England, United Kingdom|Southend University Hospital, Westcliff-on-Sea, England, United Kingdom|West Cumberland Hospital, Whitehaven, England, United Kingdom|Royal Albert Edward Infirmary, Wigan, England, United Kingdom|Royal Hampshire Hospital, Winchester, England, United Kingdom|Arrow Park Hospital, Wirral, England, United Kingdom|New Cross Hospital, Wolverhampton, England, United Kingdom|Worcester Royal Hospital, Worcester, England, United Kingdom|York Hospital, York, England, United Kingdom|York Hospital, York, England, United Kingdom|Antrim Area Hospital, Antrim, Northern Ireland, United Kingdom|Royal Victoria Hospital, Belfast, Belfast, Northern Ireland, United Kingdom|Mater Hospital, Belfast, Northern Ireland, United Kingdom|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|Altnagelvin Hospital, Derry, Northern Ireland, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom|Ninewells Hospital, Dundee, Scotland, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom|Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom|Queen Elizabeth University Hospital, Glasgow, Glasgow, Scotland, United Kingdom|Royal Alexandra Hospital, Glasgow, Paisley, Scotland, United Kingdom|Neville Hall Hospital, Abergavenny, Wales, United Kingdom|Glan Clywd Hospital, Bodelwyddan, Wales, United Kingdom|Princess of Wales Hospital, Bridgend, Wales, United Kingdom|University Hospital of Wales, Cardiff, Wales, United Kingdom|Glangwilli Hospital, Carmarthen, Wales, United Kingdom|Grange University Hospital, Cwmbran, Wales, United Kingdom|Royal Gwent Hospital, Newport, Wales, United Kingdom|Royal Glamorgan Hospital, Pontyclun, Wales, United Kingdom|Morriston Hospital, Swansea, Wales, United Kingdom|Wrexham Maelor Hospital, Wrexham, Wales, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 10000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - All-cause mortality|Days alive and not receiving organ support in ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome
NCT04347889 Preventing COVID-19 in Healthcare Workers With HCQ: A RCT Withdrawn Phase 2 Apr/20/2020 Dec/30/2020
  • Alternative id - IRB2020-00222
  • Interventions - Drug: Hydroxychloroquine|Other: Vitamin C
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - COVID-19 Seroconversion rate|Admission for Covid-19
NCT05029037 High-dose Intravenous Vitamin C (HDIVC) as Adjuvant Therapy in Critical Patients With Positive COVID-19. A Pilot Randomized Controlled Dose-comparison Trial. Not yet recruiting Phase 3 Sep/15/2021 May/15/2022
  • Alternative id - DAVCI
  • Interventions - Drug: High doses of intravenous vitamin C|Drug: Dextrose 500 mL
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 160
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Mean change in worst (highest)|Mean change in worst (lowest)|Mortality|Duration of mechanical ventilation
NCT04363216 Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment Not yet recruiting Phase 2 May/01/2020 May/01/2021
  • Alternative id - JT#15681
  • Interventions - Drug: Ascorbic Acid
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 66
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Clinical Improvement|Patient status upgraded to ICU level [Clinical decline]|Oxygen supplementation|Days with fever|Days to discharge|SAEs
NCT04530539 The Effect of Melatonin and Vitamin C on COVID-19 Active, not recruiting Not Applicable Oct/05/2020 Jun/30/2022
  • Alternative id - 2020-68
  • Interventions - Dietary Supplement: Vitamin C|Dietary Supplement: melatonin|Dietary Supplement: Placebo|Other: Symptom Survey
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Lancaster General Health, Lancaster, Pennsylvania, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care
  • Enrollment - 122
  • Age - 50 Years and older   (Adult, Older Adult)
  • Outcome measures - Symptom Severity|Symptom progression
NCT04335084 A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection Recruiting Phase 2 Jun/22/2020 Jul/01/2025
  • Alternative id - PRG-042
  • Interventions - Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ProgenaBiome, Ventura, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 600
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Prevention of COVID-19 symptoms as recorded in a daily diary|Safety as determined by presence or absence of Adverse Events and Serious Adverse Events
NCT04682574 Role of Mega Dose of Vitamin C in Critical COVID-19 Patients Recruiting Not Applicable Nov/02/2020 Jan/10/2021
  • Alternative id - IRBEC/BIH/09-2020
  • Interventions - Drug: Vitamin C
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Bahria Town International Hospital, Lahore, Punjab, Pakistan
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 15
  • Age - Child, Adult, Older Adult
  • Outcome measures - Partial pressure of Oxygen in arterial blood to fraction of inspired Oxygen (P/F ratio)|Hospital stay
NCT04482686 Trial of Combination Therapy to Treat COVID-19 Infection Active, not recruiting Phase 1 Dec/09/2020 Jul/01/2022
  • Alternative id - PRG-049
  • Interventions - Drug: Ivermectin|Drug: Doxycycline Hcl|Dietary Supplement: Zinc|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin C
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ProgenaBiome, Ventura, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 31
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to Non-Infectivity by RT-PCR|Time to Symptom progression in days as measured by NEWS scoring system (National Early Warning Score)|Time to Symptom improvement as measured by NEWS scoring system (National Early Warning Score)|Efficacy of Treatment as measured by Titer|Efficacy of Treatment as measured by RT-PCR|Safety of Treatment as Measured by D-Dimer|Safety of Treatment as Measured by Pro-Calcitonin|Safety of Treatment as Measured by C-Reactive Protein|Safety of Treatment as Measured by Ferritin|Safety of Treatment as Measured by Liver Enzymes|Safety of Treatment as Measured by Complete Blood Count|Safety of Treatment as Measured by Electrolyte Levels|Safety of Treatment as Measured by Treatment Related Adverse Events
NCT04264533 Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia Terminated Phase 2 Feb/14/2020 Mar/29/2020
  • Alternative id - 2020001
  • Interventions - Drug: VC|Drug: Sterile Water for Injection
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 56
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Ventilation-free days|28-days mortality|ICU length of stay|Demand for first aid measuments|Vasopressor days|Respiratory indexes|Ventilator parameters|APACHE II scores|SOFA scores
NCT04334967 Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Suspended Phase 4 Mar/30/2020 May/27/2022
  • Alternative id - 2020000186
  • Interventions - Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Portland Providence Medical Center, Portland, Oregon, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 13
  • Age - 45 Years and older   (Adult, Older Adult)
  • Outcome measures - Total Hospitalization|Total Mechanical Ventilation|Fever intensity measure|Shortness of breath measure|Changes in daytime cough measure|Changes in nighttime cough measure|Total mortality
NCT05150782 The Effect of Micellized Food Supplements on Health-related Quality of Life in Patients With Post-acute COVID-19 Syndrome. Not yet recruiting Not Applicable Jan/17/2022 Oct/10/2022
  • Alternative id - MyCellVSLongCOVID
  • Interventions - Dietary Supplement: Curcumin/Boswellia Serrata/Ascorbic acid mixture
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 32
  • Age - 18 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - Change in health-related quality of life|Change in patient selected functional limitations in daily life, measured with the 'Patient specific functional scale (PSFS).|Change in general health status|Change in general health|Change in Post COVID functional status measured with the 'Post COVID Functional Status' (PCFS).
NCT04446104 A Preventive Treatment for Migrant Workers at High-risk of COVID-19 Completed Phase 3 May/13/2020 Aug/31/2020
  • Alternative id - 2020/00561
  • Interventions - Drug: Hydroxychloroquine Sulfate Tablets|Drug: Ivermectin 3mg Tab|Drug: Zinc|Drug: Povidone-Iodine|Dietary Supplement: Vitamin C
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Tuas South Dormitory, Singapore, Singapore
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 4257
  • Age - 21 Years to 60 Years   (Adult)
  • Outcome measures - Laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Acute respiratory illness in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Febrile respiratory illness in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of hospitalization for COVID-19 and non-COVID-19 related indications in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of oxygen supplementation and mechanical ventilation in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Duration of oxygen supplementation and mechanical ventilation in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Length of hospital stay in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Adverse events and serious adverse events in control arm (Vitamin C)|Drug discontinuation due to adverse events in control arm (Vitamin C)
NCT04928495 Clinical Trial With N-acetylcysteine and Bromhexine for COVID-19 Not yet recruiting Phase 3 Jul/15/2021 Jun/09/2022
  • Alternative id - AVANTI-C19
  • Interventions - Drug: Vitamin C|Drug: N-acetylcysteine (NAC)|Drug: NAC + Bromhexine (BMX)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Núcleo de Biomedicina - NUBIMED, Fortaleza, Ceará, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 219
  • Age - 18 Years to 60 Years   (Adult)
  • Outcome measures - The time to recovery, defined at day 7 days follow up after enrollment, on which a patient met the criteria for category 1 or 2 on the four-category ordinal scale. [Time Frame: Day 7 follow up after enrollment.]|SARS-CoV-2 RNA viral load measurements change. [ Time Frame: Change between Day 1 and Day 7 follow up after enrollment. ]|Proportion of patients with qualitative serum IgM / IgG. [ Time Frame: Proportion of positive patients at Day 7 for IgM / IgG (N; %). ]|Biomarkers (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1, IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I, CRP and procalcitonin) measurements change. [ Time Frame: Change between Day 1 and Day 14 follow up after enrollment. ]
NCT04570254 Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19 Completed Not Applicable Aug/19/2020 Dec/01/2020
  • Alternative id - 09-CEI-011-20160627
  • Interventions - Drug: Vitamin C|Drug: Vitamin E|Drug: Melatonin|Drug: N-acetyl cysteine|Drug: Pentoxifylline
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Unidad Temporal COVID-19 en Centro Citibanamex, Mexico City, Mexico
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 110
  • Age - Child, Adult, Older Adult
  • Outcome measures - Death from any cause|Percentage of patients who required orotracheal intubation|Assisted mechanical ventilation|Stay in an intensive care unit|Measure lipoperoxidation in basal and post-therapy samples|Evaluation of the total antioxidant capacity|Oxidative and antioxidant stress|Effect of antioxidant therapy at the level on organ failure secondary to SARS-COV2
NCT04354428 Treatment for COVID-19 in High-Risk Adult Outpatients Active, not recruiting Phase 2|Phase 3 Apr/16/2020 Jan/01/2021
  • Alternative id - STUDY00009878|INV-017062
  • Interventions - Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid|Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 300
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only]|Rate of participant-reported adverse events|COVID-19-related hospitalization days|Rate of disease severity|Viral shedding rates|Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only]
NCT03680274 Lessening Organ Dysfunction With VITamin C Active, not recruiting Phase 3 Nov/08/2018 Dec/31/2022
  • Alternative id - MP-31-2019-2945
  • Interventions - Drug: Vitamin C|Other: Control
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Research Center of the CHUS, Sherbrooke, Quebec, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 800
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of deceased participants or with persistent organ dysfunction|Number of participants with persistent organ dysfunction-free days in intensive care unit|Number of participants deceased at 6 months|Score of health related quality of life in 6-month survivors|Global tissue dysoxia|Organ function (including renal function)|Rate of inflammation|Rate of infection|Rate of endothelial injury|Occurrence of stage 3 acute kidney injury|Acute hemolysis|Hypoglycemia|Vitamin C volume of distribution|Vitamin C clearance|Vitamin C plasma concentration
NCT04712357 Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19 Recruiting Not Applicable Nov/09/2020 Jan/01/2023
  • Alternative id - CAAE: 34182620.0.0000.5045
  • Interventions - Drug: Vitamin C 500 MG Oral Tablet|Drug: Tenofovir disoproxyl fumarate 300 MG Oral Tablet|Drug: Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Núcleo de Biomedicina - NUBIMED, Fortaleza, Ceará, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 219
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - The time to recovery, defined at day 7 days follow up after enrollment, on which a patient met the criteria for category 1, 2, or 3 on the eight-category ordinal scale.|SARS-CoV-2 RNA viral load measurements change.|Proportion of patients with qualitative serum IgM / IgG.|Biomarkers (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1, IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I, CRP and procalcitonin) measurements change.
NCT04323514 Use of Ascorbic Acid in Patients With COVID 19 Unknown status Not Applicable Mar/13/2020 Mar/13/2021
  • Alternative id - 3143
  • Interventions - Dietary Supplement: Vitamin C
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - A.R.N.A.S. Civico - Di Cristina - Benfratelli, Palermo, Italy
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 500
  • Age - Child, Adult, Older Adult
  • Outcome measures - In-hospital mortality|PCR levels|Lactate clearance|Hospital stay|Symptoms|Positive swab|Tomography imaging
NCT04664010 Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19) Active, not recruiting Not Applicable Feb/06/2020 Jan/31/2021
  • Alternative id - XianInternationalMCH_HXJ
  • Interventions - Drug: Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C|Drug: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose|Drug: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Xi'an International Medical Center Hospital, Xi'an, Shaanxi, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Recovery time|Time of disappearance of fever symptoms|The rate of conversion from COVID-19 positive to COVID-19 negative|Time of disappearance of cough|Respiratory rate|Blood oxygen saturation|PaO2|PaCO2|The time of obvious improvement as shown on chest CT scans relative to admission|The rate of obvious improvement as shown on chest CT scans relative to admission|Levels of C-reactive protein|Erythrocyte sedimentation rate|Levels of Procalcitonin|Levels of interleukin-6|Levels of interleukin-10|Levels of tumor necrosis factor-alpha
NCT04828538 Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19 Active, not recruiting Not Applicable Jan/01/2021 Nov/30/2021
  • Alternative id - MCI102020
  • Interventions - Dietary Supplement: Vitamin D|Dietary Supplement: Omega DHA / EPA|Dietary Supplement: Vitamin C, Vitamin B complex and Zinc Acetate|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital de Soledad, San Luis Potosí, SLP, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other
  • Enrollment - 1800
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Covid infection rate (PREVENT Trial only)|Incidence of severe outcome (TREAT Trial only)|Incidence of hospitalization and death (PREVENT Trial only)|Length of hospitalization and death after discharge (TREAT Trial only)
NCT04395768 International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Recruiting Phase 2 Sep/09/2020 Dec/31/2021
  • Alternative id - Alliance-COVID19
  • Interventions - Dietary Supplement: Vitamin C|Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Zinc Citrate|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin B12
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - National Institute of Integrative Medicine, Melbourne, Victoria, Australia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 200
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Symptoms|Length of hospital stay|invasive mechanical ventilation or mortality|Mortality|mechanical ventilation|oxygen|ICU|days in hospital|days in ICU|renal replacement therapy|Extracorporeal support
NCT04370288 Clinical Application of Methylene Blue for Treatment of Covid-19 Patients Recruiting Phase 1 Apr/19/2020 Sep/21/2020
  • Alternative id - IR.MUMS.REC.1399.122
  • Interventions - Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Imam Reza Hospital, Mashhad, Razavi Khorasan, Iran, Islamic Republic of
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 20
  • Age - 18 Years to 90 Years   (Adult, Older Adult)
  • Outcome measures - Proportion of patients remaining free of need for mechanical ventilation in both groups|Mortality rate in both groups|Improvement in Pa02/Fi02 ratio in both groups|Duration of hospital stay in both group.|Duration of Intensive Care Unit stay in both groups|Days free of dialysis in both groups|C-reactive proteins|WBC Count
NCT04344184 SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI) Active, not recruiting Phase 2 Dec/18/2020 Jun/01/2022
  • Alternative id - HM20018977
  • Interventions - Drug: L-ascorbic acid|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 48
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Change in COVID disease status|Renal safety biomarkers - serum oxalate|Renal safety biomarkers - urine oxalate stones|Renal safety biomarkers - 24-hour urine oxalate levels|Acute Kidney Injury-free days|Number of deaths|Change in plasma ferritin levels|Change in plasma D-dimer levels|Change in serum lactate dehydrogenase (LDH) levels|Change in plasma IL-6 levels|Proportion of patients alive and free of respiratory failure|Proportion of patients alive and free of invasive mechanical ventilation
NCT04468139 The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19 Recruiting Phase 4 Jun/20/2020 Jul/30/2020
  • Alternative id - 20-95M
  • Interventions - Drug: Quercetin|Dietary Supplement: bromelain|Drug: Zinc|Drug: Vitamin C
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Ministry of health.First health cluster ,Riaydh, Riyadh, Saudi Arabia
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - days of stay at hospital after treatment and discharge|serum zinc before and after treatment|questionnaire including parameters like BMI,,smoking , underling diseases, immunological treatment ,|day of negative conversion for nasopharyngeal swab for rt-PCR FOR covid-19
NCT04710329 High-Dose Vitamin C Treatment in Critically Ill COVID-19 Patients Completed Jan/16/2021 Feb/10/2021
  • Alternative id - CVIT-3334
  • Interventions - Drug: Ascorbic acid
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Sisli etfal training and resource hospital, Sisli, İstanbul, Turkey
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 78
  • Age - 18 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - short term mortality|Length of Intensive Care Unit Stay|vasopressor requirement|invasive mechanical ventilation requirement|PaO2/FiO2 ratio|C-reactive protein|procalcitonin|Lymphocyte count|ferritin|SOFA
NCT04780061 Dietary Supplements for COVID-19 Recruiting Phase 3 Jul/12/2021 Dec/01/2022
  • Alternative id - 20210072-01H
  • Interventions - Drug: Vitamin D3 50,000 IU|Dietary Supplement: Vitamin C/Zinc|Dietary Supplement: Vitamin K2/D|Other: Microcrystalline Cellulose Capsule|Other: Medium Chain Triglyceride Oil
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - The Centre for Health Innovation, Ottawa, Ontario, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 200
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Participant-reported overall health|Effect of COVID-19 on the health status of participants|Symptom Severity of common COVID-19 symptoms|Total symptom duration|Incidence of delayed return to usual health|Frequency of Hospitalizations|Hospital Length of Stay|All-cause mortality
NCT04357782 Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation Completed Phase 1|Phase 2 Apr/16/2020 Oct/13/2020
  • Alternative id - Davis 001
  • Interventions - Drug: L-ascorbic acid
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Hunter Holmes Mcguire Veteran Affairs Medical Center, Richmond, Virginia, United States
  • Study designs - Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 20
  • Age - 18 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - Number of Participants With Adverse Events Related to High Dose Intravenous Vitamin C (HDIVC)|Number of Participants With Serious Adverse Reactions|Number of Participants With Adverse Reactions|Ventilator-free Days|Intensive Care Unit (ICU)-Free Days|Hospital-free Days|All-cause Mortality|Change in S/F Ratio During High Dose Intravenous Vitamin C (HDIVC)|C-reactive Protein (CRP)|Lactate Dehydrogenase (LDH)|D-dimer|Lymphocyte Count|Neutrophil to Lymphocyte Ratio (NLR)|Serum Ferritin
NCT04558424 RCT,Double Blind, Placebo to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMU Not yet recruiting Not Applicable Oct/01/2020 Sep/01/2021
  • Alternative id - BSMMU 2020
  • Interventions - Dietary Supplement: zinc gluconate and ascorbic acid
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care
  • Enrollment - 50
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - symptoms reduction time frame|Symptom Resolution: Fever|Symptom Resolution: Cough|Symptom Resolution: Fatigue|Symptom Resolution: Muscle/body aches|Symptom Resolution: Headache|Symptom Resolution: New loss of taste|Symptom Resolution: New loss of smell|Symptom Resolution: Congestion/ runny nose|Symptom Resolution: Nausea|Symptom Resolution: Vomiting|Symptom Resolution: Diarrhea|Day 5 Symptoms|Severity of Symptoms|Adjunctive Medications|Supplementation Side Effects
NCT04279197 Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu Completed Phase 2 Apr/23/2020 Mar/24/2021
  • Alternative id - Fzhy-ncp-2
  • Interventions - Drug: Fuzheng Huayu Tablet|Drug: Vitamin C tablets|Drug: Placebo|Other: respiratory function rehabilitation training
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Shuguang Hospital, Shanghai, Shanghai, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 142
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - The improvement proportion of pulmonary fibrosis|The improvement of lung function|The improvement proportion of pulmonary inflammation|The improvement proportion of clinical symptom|Quality of Life-BREF (QOL-BREF)|Patient Health Questionnaire-9(PHQ-9)|Generalized anxiety disorder-7(GAD-7)|The 6-minute walk distance
NCT04401150 Lessening Organ Dysfunction With VITamin C - COVID-19 Recruiting Phase 3 Aug/14/2020 Dec/01/2022
  • Alternative id - MP-31-2021-3741
  • Interventions - Drug: Vitamin C|Drug: Control
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Research Center of the CHUS, Sherbrooke, Quebec, Canada|Research Centre of the CHUS, Sherbrooke, Quebec, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 800
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Death or persistent organ dysfunction|Number of intensive care unit-free days|Persistent organ dysfunction-free days in ICU|Number of patients deceased at 6 months|Health related quality of life in 6-month survivors|Organ function|Global tissue dysoxia|Rate of inflammation|Rate of infection|Rate of endothelial injury|Occurrence of stage 3 acute kidney injury|Acute hemolysis|Hypoglycemia|Vitamin C volume of distribution|Vitamin C clearance|Vitamin C plasma concentration
NCT04334512 A Study of Quintuple Therapy to Treat COVID-19 Infection Recruiting Phase 2 Jun/22/2020 Sep/01/2024
  • Alternative id - PRG-044
  • Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ProgenaBiome, Ventura, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 600
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - The rate of recovery of mild or moderate COVID-19 in patients using Quintuple Therapy|Reduction or Progression of Symptomatic Days|Assess the safety of Quintuple Therapy|Assess the safety of Quintuple Therapy via pulse|Assess the safety of Quintuple Therapy via oxygen saturation|Assess the safety of Quintuple Therapy via EKG|Assess Tolerability of Quintuple Therapy
NCT04328961 Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) Completed Phase 2|Phase 3 Mar/31/2020 Oct/08/2020
  • Alternative id - STUDY00009750|INV-016204
  • Interventions - Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid
  • Study type - Interventional
  • Study results - Has Results
  • Locations - University of California Los Angeles, Los Angeles, California, United States|Tulane, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 943
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection|The Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection|Rate of Participant-reported Adverse Events|Number of Participants Who Had COVID-19 Disease
NCT04342728 Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation Completed Not Applicable Apr/08/2020 Feb/11/2021
  • Alternative id - IRB 20-361
  • Interventions - Dietary Supplement: Ascorbic Acid|Dietary Supplement: Zinc Gluconate|Dietary Supplement: Ascorbic Acid and Zinc Gluconate|Other: Standard of Care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Cleveland Clinic, Weston, Florida, United States|Cleveland Clinic, Cleveland, Ohio, United States
  • Study designs - Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care
  • Enrollment - 214
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Symptom Reduction|Symptom Resolution: Fever|Symptom Resolution: Cough|Symptom Resolution: Shortness of Breath|Symptom Resolution: Fatigue|Symptom Resolution: Muscle/body aches|Symptom Resolution: Headache|Symptom Resolution: New loss of taste|Symptom Resolution: New loss of smell|Symptom Resolution: Congestion/ runny nose|Symptom Resolution: Nausea|Symptom Resolution: Vomiting|Symptom Resolution: Diarrhea|Day 5 Symptoms|Hospitalizations|Severity of Symptoms|Adjunctive Medications|Supplementation Side Effects
Export (.csv)